[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"quality-of-life\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:quality-of-life":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,379,0,25,[9,46,81,107,136,163,184,206,237,267,290,319,347,371,393,420,447,471,504,535,565,594,624,661,684],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053312","a-randomized-control-trial-of-conversations-advancing-resilience-and-empowerment-care-intervention-100053312",false,"NCT07698964","A Randomized Control Trial of Conversations Advancing Resilience and Empowerment (CARE) Intervention","A Randomized Control Trial of Conversations Advancing Resilience and Empowerment (CARE): A Peer-Led Intervention to Improve Health Among Communities in Texas","CARE","Inclusion Criteria:\n\n* Females between the ages of 18-49\n* Self-report at least one risk factor cardiovascular disease (e.g. high blood pressure, high cholesterol, diabetes, overweight, and family history of heart disease).\n* Reside in one of the priority communities will be eligible to participate in the study.\n* Meet minimum digital literacy criteria, defined as having a working and readily accessible email address and using a smart device daily for texting, calling, and checking email.\n\nPriority communities for the South Texas site include Harris, Hidalgo, Cameron, Willacy, Starr, and Nueces counties plus surrounding coastal communities served by South Coastal AHEC.\n\nExclusion Criteria:\n\n* Those not meeting the inclusion criteria will not be eligible to participate",true,"FEMALE","18 Years","49 Years",{"count":23,"type":24},200,"ESTIMATED","INTERVENTIONAL",[27],"NA","The investigators propose to implement and evaluate the effectiveness of the peer-led CARE Intervention designed to mitigate health differences among rural and low-income communities in Texas. This intervention leverages the expertise of Community Health Workers (CHWs) to empower rural and low-income communities, improving health outcomes through outreach, education, counseling, and social support.",[30,31,32],"Quality of Life","Health Promotion","Blood Pressure Monitoring, Self","RECRUITING","2026-07-07",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-06-02",{"date":41,"type":24},"2027-03-31",{"name":43,"class":44},"University of Texas Rio Grande Valley","OTHER",2,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":25,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100541211","capable-transplant-100541211","NCT06326905","CAPABLE Transplant","Addressing Inactive Kidney Transplant Waitlist Status Through Adapting a Tailored Psycho-Social-Environmental Program","Inclusion Criteria:\n\n* Deceased Donor Waitlist\n* ≥18 years old\n* Community dwelling\n* Current Inactive status or active and had been inactive in the last 18 months for cardiovascular disease, frailty, obesity, social support, mental health, incomplete testing OR Active on the waitlist and low-income\n\nExclusion Criteria:\n\n* Living Donor Waitlist\n* Severe cognitive impairment\n* Inactivity expected to last \\> 3 months (eg cancer treatment)\n* \\>4 hospitalizations in the last 12 months\n* Current home nursing, physical or occupational therapy","ALL","99 Years",{"count":56,"type":24},43,[27],"The purpose of this mixed methods study is to adapt CAPABLE as CAPABLE Transplant to accomplish two things: 1) To resolve barriers to being classified as active on the Kidney Transplant (KT) waitlist, 2) as a surgical prehabilitation intervention targeting the pre-frail\u002F frail KT waitlist population. It consists of two phases- an open label pilot and a randomized waitlist control trial, and 3) pilot test the feasibility and acceptability for CAPABLE Transplant in symptom and waitlist specific metrics amongst low-income active kidney transplant waitlist candidates.",[30,60,61,62],"Depression","End Stage Renal Disease","Disability Physical",[64,65,66,67,68,69,70,61],"Activities of Daily Living","Instrumental Activities of Daily Living","Physical Function","Executive Function","Home","Intervention","Kidney Transplant","2026-06-30",{"date":73,"type":37},"2026-07-02",{"date":75,"type":37},"2025-01-25",{"date":77,"type":24},"2026-07-01",{"name":79,"class":44},"Johns Hopkins University",1,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":25,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100589500","effect-of-alcohol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-women-with-ovarian-endometriosis-100589500","NCT06955221","Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis","Effect of US-guided Alcohol Sclerotherapy for Endometriomas on Pelvic Pain and Quality of Life","ESCOMA","Inclusion Criteria:\n\n* Female sex\n* Age ≥18 and ≤45 years\n* Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm\n* Size between 30-100 mm, persistent for at least 3-6 months since diagnosis\n* Ca125 marker \\\u003C300 UI\u002FmL and HE4 \\\u003C 70 pM\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* History of ovarian or uterine cancer\n* Endometrioma size \\\u003C30 mm or \\>100 mm\n* Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause\n* Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy\n* Ca125 \\>300 UI\u002FmL\n* HE4 \\>70 pM\n* Pregnant women\n* Patients who do not wish to participate in the study or who are mentally incapacitated","45 Years",{"count":91,"type":24},288,[27],"The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management.\n\nThe main questions it aims to answer are:\n\n1. \\- Does sclerotherapy significantly reduce pelvic pain compared to expectant management?\n2. \\- Does sclerotherapy improve quality of life as measured by the EHP-5 score?\n\nResearchers will compare the sclerotherapy group to the expectant management group to determine whether the intervention leads to greater improvement in pain and quality of life.\n\nParticipants will:\n\n* Be randomly assigned to one of two groups: (1) Sclerotherapy group: undergo ultrasound-guided puncture and alcohol sclerotherapy; (2) Control group: expectant management\n* Complete quality of life and pain assessments at baseline and after 6 months\n* Provide blood and urine samples for biomarker analysis (e.g., cortisol, IL-6, hsCRP, catecholamines)\n* Undergo ovarian reserve assessments (AMH, antral follicle count)\n* Be followed for adverse events, recurrence, fertility outcomes, and treatment-related costs\n\nThe study will follow an intention-to-treat and per-protocol analysis approach.",[95,96,30,97],"Endometrioma","Ultrasound Therapy; Complications","Pelvic Pain","2026-06-27",{"date":77,"type":37},{"date":101,"type":37},"2025-01-01",{"date":103,"type":24},"2027-12-31",{"name":105,"class":44},"Hospital Universitari de Bellvitge",28,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100645122","cognitive-function-and-quality-of-life-in-obstructive-sleep-apnea-100645122","NCT07678918","Cognitive Function and Quality of Life in Obstructive Sleep Apnea","Correlation Between the Cognitive Function and Quality of Life in Patients With OSA","Inclusion Criteria:\n\n* Patients Group: Age \\> 18 years.\n* Patients Group: Meeting the AASM diagnostic criteria for OSA.\n* Control Group: Age and sex-matched community members related to the patients.\n* Control Group: Education level, social status, and comorbidity-matched people.\n\nExclusion Criteria:\n\n* Patients Group: OSA patients who are compliant on PAP therapy (\\> 4 hours, \\> 5 nights\u002Fweek) for ≥ 6 months.\n* Patients Group: Inability to comprehend and\u002For co-operate with the instructions provided by the investigators during neurocognitive function assessment.\n* Patients Group: History of neurological comorbidities with potential cognitive impairment (previous cerebrovascular stroke, dementia).\n* Patients Group: Patients who are maintained on medications that potentially impair cognitive performance (histamine receptor antagonist, antipsychotic, antidepressant, or mood stabilizer drugs).\n* Patients Group: Use of alcohol, or illicit drugs that interfere with cognitive function (cannabis, opioids, amphetamine or equivalents).\n* Control Group: Intermediate or high-risk of having undiagnosed OSA as assessed by the STOP-BANG questionnaire.",{"count":115,"type":24},86,"OBSERVATIONAL","Obstructive Sleep Apnea (OSA) is a common condition that disrupts normal breathing during sleep. Beyond causing daytime tiredness, OSA can also impact a person's cognitive functions, such as their attention span, memory, and problem-solving skills, which may in turn affect their overall quality of life.\n\nThe main purpose of this study is to compare the thinking and memory skills of adults recently diagnosed with OSA against a control group of healthy adults without the condition. Furthermore, the researchers aim to understand how specific cognitive challenges (like difficulty sustaining attention) relate to a patient's physical and mental well-being.\n\nParticipants in the study will undergo an overnight sleep test (diagnostic polysomnography) at a sleep clinic. Shortly after the sleep test, participants will complete a series of short, computer-based tasks designed to measure their attention, memory, and executive function. They will also be asked to fill out standard questionnaires regarding their daily sleepiness, mood, and health-related quality of life.",[119,120,30],"Obstructive Sleep Apnea","Cognitive Impairment",[119,122,30,123,124,125,126],"Cognitive Function","Neurocognitive Impairment","Psychomotor Vigilance","Polysomnography","SF-36","NOT_YET_RECRUITING","2026-06-25",{"date":77,"type":37},{"date":131,"type":24},"2026-08",{"date":133,"type":24},"2027-09",{"name":135,"class":44},"Assiut University",{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":25,"phases":145,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":80},"100645190","immersive-virtual-reality-applied-to-therapeutic-physical-exercise-in-cellular-therapy-100645190","NCT07679958","Immersive Virtual Reality Applied to Therapeutic Physical Exercise in Cellular Therapy","RVI-ET","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Signed informed consent.\n* Patients eligible for CT scan at the Alvaro Cunqueiro Hospital.\n* Patients capable of performing therapeutic exercise independently, based on an objective initial functional assessment.\n* The clinical investigator, in their professional judgment, determines that the patient can adhere to all study requirements.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Any medical condition or mental illness that could interfere with understanding HIP and CI.\n* Patients participating in another clinical trial.\n* Balance disorders that increase the risk of falls.\n* Severe visual and\u002For auditory impairments that prevent participation in the session.\n* History of vertigo, seizures, or epileptic fits.",{"count":144,"type":24},144,[27],"Cell therapy (CT), including hematopoietic stem cell transplantation (HSCT) and advanced CAR T-cell therapies, is used for the treatment of oncohematological and other diseases. HSCT is associated with treatment-related toxicities, including fatigue, muscle weakness, and reduced functional capacity due to intensive conditioning chemotherapy, immunosuppressive treatments, corticosteroids, and complications such as infections or graft-versus-host disease. Emotional symptoms, including anxiety, depression, fear, and frustration, also affect patients' recovery and ability to regain functional independence. Evidence indicates that exercise interventions improve emotional well-being, fatigue, quality of life, physical function, cardiovascular fitness, and muscle mass in patients with hematological malignancies and HSCT recipients.\n\nVirtual reality (VR) has emerged as an innovative tool in rehabilitation, supporting patient motivation, exercise guidance, and monitoring. Immersive virtual reality (IVR), through head-mounted displays and multisensory environments, enhances the sense of presence and engagement. Studies suggest that IVR-based exercise programs are feasible, improving functional abilities, quality of life, satisfaction, and adherence.\n\nSince 2017, a Therapeutic Exercise program for patients admitted for HSCT has been implemented at Álvaro Cunqueiro Hospital (Vigo) through collaboration between the Physiotherapy Unit and the Hematology Department. Before admission, patients undergo a physical assessment, receive an individualized exercise plan, education, and a therapeutic exercise guide. Based on clinical experience, the team hypothesizes that integrating IVR into therapeutic exercise may improve motivation, adherence, and emotional well-being during hospitalization.",[148,149,150,30,151],"Hematologic Diseases","Hematopoietic Stem Cell Transplantation","Cellular Therapy","Oncologic Disorders",[153,154,155],"Therapeutic Exercise","Immersive virtual reality","Cellular therapy",{"date":77,"type":37},{"date":158,"type":24},"2026-07-24",{"date":160,"type":24},"2029-06-01",{"name":162,"class":44},"Fundacin Biomedica Galicia Sur",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":53,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":80},"100645027","psychometric-properties-of-the-turkish-version-of-the-staffordshire-adolescent-idiopathic-scoliosis-questionnaire-100645027","NCT07676019","Psychometric Properties of the Turkish Version of the Staffordshire Adolescent Idiopathic Scoliosis Questionnaire","Psychometric Properties of the Turkish Version of the Staffordshire Adolescent Idiopathic Scoliosis Questionnaire (SQAIS)","Inclusion Criteria\n\n* Aged between 10 and 19 years.\n* Diagnosed with Adolescent Idiopathic Scoliosis (AIS) by an orthopedic surgeon or spine specialist.\n* Able to read and understand Turkish.\n\nExclusion Criteria\n\n* Diagnosis of congenital, neuromuscular, or syndromic scoliosis.\n* History of severe neurological, psychiatric, or cognitive disorders.\n* Presence of communication impairments that may interfere with understanding or completing the questionnaires.\n* History of major trauma or spinal surgery within the previous 6 months.","10 Years","19 Years",{"count":173,"type":24},100,"Patient-Reported Outcome Measures (PROMs) have gained increasing importance in scoliosis research in recent years. Although widely used instruments such as the Scoliosis Research Society-22 (SRS-22) include domains related to body image, their primary purpose is to assess overall health-related quality of life and functional outcomes. In contrast, the Staffordshire Questionnaire for Adolescent Idiopathic Scoliosis (SQAIS) was specifically developed to provide a more detailed and patient-centered evaluation of body image and perceived deformity in individuals with adolescent idiopathic scoliosis (AIS). However, a Turkish version of the questionnaire with established validity and reliability is not currently available.\n\nTherefore, the aim of the planned master's thesis is to conduct the cultural adaptation of the Staffordshire Questionnaire for Adolescent Idiopathic Scoliosis into Turkish and to evaluate its psychometric properties in adolescents with AIS. The study will involve a systematic process of linguistic translation and cross-cultural adaptation. Subsequently, the validity and reliability of the Turkish version will be assessed through analyses of internal consistency, test-retest reliability, construct validity, and criterion validity.\n\nThe findings of this study are expected to provide a valid and reliable instrument for assessing body image and deformity perception among Turkish adolescents with idiopathic scoliosis, thereby contributing an important patient-centered outcome measure to both clinical practice and research.",[176,30],"Scoliosis","2026-06-24",{"date":71,"type":37},{"date":73,"type":24},{"date":181,"type":24},"2027-03-02",{"name":183,"class":44},"Acibadem University",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":25,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":4},"100644580","care-burden-and-qualty-of-lfe-100644580","NCT07672340","Care Burden And Qualıty of Lıfe","Effect Of Multıdımensıonal Traınıng Applıed to Caregıvers of Home Health Servıce Recıpıents Aged 65 And Over on Care Burden And Qualıty of Lıfe","Care Burden","Inclusion Criteria:\n\nBe willing to participate in the study\n\n* Be literate\n* Have registered with a home health care unit\n* Have been responsible for the care of a relative aged 65 or older for at least one month\n* Score at least 21 on the Zarit Caregiver Burden Scale\n\nExclusion Criteria:\n\n* • Having severe reading comprehension difficulties\n\n  * Having severe hearing difficulties\n  * Having been diagnosed with a psychiatric disorder (schizophrenia, bipolar disorder, or anxiety disorder)\n  * Failing to complete the data collection instruments used in the study\n  * Failing to attend at least two training sessions",{"count":193,"type":24},78,[27],"This randomized controlled trial will be conducted to examine the effect of a multidimensional training program, to be implemented by a public health nurse, on the care burden and quality of life of primary caregivers of patients aged 65 and older.",[197,30,198],"Caregiver Burden","Public Health",{"date":200,"type":37},"2026-06-26",{"date":202,"type":24},"2026-07",{"date":131,"type":24},{"name":205,"class":44},"Aydin Adnan Menderes University",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":25,"phases":217,"briefSummary":218,"conditions":219,"keywords":225,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":80},"100645009","empowerher-hybrid-digital-intervention-for-breast-cancer-survivors-100645009","NCT07676591","EmpowerHer: Hybrid Digital Intervention for Breast Cancer Survivors","EmpowerHer: Protocol for a Multicentre Randomized Controlled Trial Evaluating a Hybrid Digital Exercise and Education Intervention for Breast Cancer Survivors Across Five European Countries","EmpowerHer","Inclusion Criteria:\n\n* Women aged 18-65 years.\n* History of breast cancer.\n* Completed primary treatment (surgery, chemotherapy, and\u002For radiotherapy; adjuvant hormone therapy is permitted).\n* No evidence of active or metastatic disease at enrolment.\n* Able to provide informed consent and communicate in the local language.\n* Own and are able to use a smartphone.\n* Willing to engage in the exercise program.\n\nExclusion Criteria:\n\n* Cognitive impairment preventing safe participation or questionnaire completion.\n* Uncontrolled medical conditions that contraindicate exercise (e.g., unstable cardiac disease).\n* Concurrently enrolled in another structured exercise or survivorship study.\n* Pregnant or breastfeeding.","65 Years",{"count":216,"type":24},147,[27],"The goal of this clinical trial is to learn if a 12-week hybrid exercise and education program (EmpowerHer) works to improve health-related quality of life in breast cancer survivors aged 35 to 65.\n\nThe main questions it aims to answer are:\n\n* Does the EmpowerHer program improve the everyday quality of life of participants?\n* Does the program lower fatigue, anxiety, and depression while raising physical fitness?\n\nResearchers will compare the EmpowerHer program to usual medical care to see if the program works better to help survivors recover.\n\nParticipants will:\n\n* Use a mobile application at home at least twice a week for structured exercise.\n* Read short educational modules on the mobile application about health after cancer.\n* Attend weekly in-person motivational group sessions with a program facilitator.\n* Complete health and physical tests at the start, at 12 weeks, and 3 months later.",[220,221,30,222,223,224],"Breast Cancer","Cancer Survivors","Exercise Therapy","Social Support","Mobile Applications",[226,222,227,224,223,228,30],"Breast Cancer Survivors","Digital Health","Multicentre Randomized Controlled Trial","2026-06-23",{"date":71,"type":37},{"date":232,"type":24},"2027-07-01",{"date":234,"type":24},"2028-06-30",{"name":236,"class":44},"University of Valencia",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":18,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":25,"phases":247,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":80},"100591673","structural-heat-adaptation-and-education-in-rural-setting-100591673","NCT06983483","Structural Heat Adaptation and Education in Rural Setting","Structural Heat Adaptation and Education in Rural Setting (SHAPES Trial)","SHAPES","Inclusion Criteria:\n\n* All households within the selected clusters who provide consent.\n\nExclusion Criteria:\n\n* Households planning to move away from the study site within the next 6 months\n* Individuals with severe mental or physical health conditions that preclude participation",{"count":246,"type":24},7128,[27],"This study aims to understand whether simple, low-cost interventions, such as improved home cooling, practical advice, and minor home modifications, can help protect people's health and quality of life during periods of extreme heat in rural, low-income villages of Matiari, Pakistan.\n\nKey Questions the Study Seeks to Answer:\n\n1. Can these interventions reduce heat-related health problems such as dizziness, headaches, and heatstroke and improve quality of life?\n2. Can they lower indoor temperatures and improve sleep quality, comfort, and daily functioning?\n\nTo answer these questions, researchers will compare communities where families receive heat-related support and information with similar communities that do not, to assess any differences in health and well-being. Endline venous blood sampling will be conducted for biobanking only.\n\nWhat Participants Can Expect:\n\n* Answer questions about their health, living conditions, and how they cope with heat\n* Have small temperature sensors placed inside their homes\n* Some participants may wear a lightweight wristband that tracks sleep and heart rate\n* In selected households, cooling improvements will be made, such as adding shade, applying reflective roof paint, or enhancing airflow\n\nPurpose:\n\nThis study seeks to identify affordable and effective strategies to help families stay safe during extreme heat, and to use these insights to support other vulnerable communities facing similar challenges.",[250,30],"Heat Illness",[252,253,254,255,256,257,258,259],"heat illness","behaviour modification","personal cooling","Structural modification","heat adaptation","prevention","rural","Quality of life",{"date":128,"type":37},{"date":262,"type":37},"2026-01-01",{"date":264,"type":24},"2028-02",{"name":266,"class":44},"Aga Khan University",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":25,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":289},"100499528","single-vs-multiple-fraction-trial-of-stereotactic-ablative-radiotherapy-for-comprehensive-treatment-of-oligometastasesprogression-100499528","NCT05784428","Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases\u002FProgression","Single vs. Multiple Fraction Non-Inferiority Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligo-metastases\u002FProgression: SIMPLIFY-SABR-COMET","Inclusion Criteria:\n\n* 1-5 current oligometastatic or oligo-progressive lesions\n* Age 18 years or older\n* Able to provide informed consent\n* Able to complete electronic entry of patient reported outcomes and questionnaires independently or with assistance from a caregiver\u002Ffamily\u002Ffriend\u002Fresearch staff using electronic methods after providing consent to email use.\n* Life expectancy \\> 6 months\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Controlled primary tumor: defined as at least 3 months since original tumor treated radically, with no progression at primary site (can be considered controlled if no evidence of the primary tumour on imaging \\[e.g. primary unknown\\])\n* A history and physical examination, including ECOG performance status, performed within 6 weeks prior to enrollment\n* Patient has had a CT chest, abdomen and pelvis or PET-CT within 10 weeks prior to enrollment, and within 13 weeks prior to treatment\n* Patient has had a nuclear bone scan (if no positron emission tomography-computed tomography \\[PET-CT\\]) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment\n* Patient has had CT or MRI brain imaging if primary has a propensity for central nervous system metastases (if deemed appropriate by the treating investigator) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment.\n* For patients with known spine metastases, patient has had MRI spine imaging within 10 weeks prior to enrollment, and with 13 weeks prior to treatment.\n* If solitary lung nodule for which biopsy is unsuccessful or not possible, patient has had an FDG (fluorodeoxyglucose) PET scan or CT (chest, abdomen, pelvis) and bone scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment\n* If colorectal primary with rising Carcinoembryonic antigen (CEA), but equivocal imaging, patient has had an FDG PET scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment\n* Patient is judged able to:\n\n  * Maintain a stable position during therapy\n  * Tolerate immobilization device(s) that may be required to deliver SABR safely\n* Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date\n\nExclusion Criteria:\n\n* Uncontrolled concurrent malignant cancer\n* Lesion in femoral bone requiring surgical fixation\n* No chemotherapy agents (cytotoxic, or molecularly targeted agents) will be used within the period of time commencing 1 week prior to radiation, lasting until 1 week after the last fraction. See section 5.3.3 regarding this criterion.\n* Serious medical comorbidities precluding radiotherapy. These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI) tract will receive radiotherapy, and connective tissue disorders such as lupus or scleroderma.\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, similar biological effective dose calculations should be used to equate previous doses to the tolerance doses listed below. All such cases should be discussed with the local and study principal investigators (PIs).\n* Current malignant pleural effusion\n* Liver metastases located in the \"Biliary no fly zone\" defined for this trial as common biliary track, cystic duct and distal branches (1 cm) + 5 mm.\n* Inability to treat all sites of oligometastatic or oligoprogressive disease\n* Presence of brain metastases as the sole site of disease\n* Maximum size of 5 cm for lesions outside the brain, except:\n\n  * Bone metastases over 5 cm may be included, if in the opinion of the local PI it can be treated safely (e.g. rib, scapula, pelvis)\n* Any brain metastasis \\> 3.5 cm in size or a total volume of brain metastases greater than 30 cc is excluded\n* Clinical or radiologic evidence of spinal cord compression. Patients can be eligible if surgical resection has been performed\n* Patients with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of \\>12\n* Dominant brain metastasis requiring surgical decompression\n* Surgical resection of all metastases (i.e. no lesion available to be treated with SABR)\n* Complete response to systemic therapy, defined as the absence of visible disease on imaging\n* Pregnant or breast feeding",{"count":275,"type":24},598,[27],"Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, quality of life (QoL), and cost-effectiveness. In a subset of patients, we will also compare patient QoL, hospitalization rates, and cost-effectiveness between patients who complete QoL questionnaires, record symptoms and receive healthcare provider-guided intervention vs. patients who complete QoL questionnaires only.",[279,280,281,30],"Oligometastatic Disease","Oligoprogression","Toxicity Due to Radiotherapy",{"date":128,"type":37},{"date":284,"type":37},"2025-04-16",{"date":286,"type":24},"2035-05-30",{"name":288,"class":44},"Robert Olson",14,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":25,"phases":300,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":80},"100634965","photobiomodulation-in-chronic-fatigue-syndrome-100634965","NCT07546539","Photobiomodulation in Chronic Fatigue Syndrome","The Role of Photobiomodulation in Patients With Chronic Fatigue Syndrome","Inclusion Criteria\n\n* Age 18-60 years\n* Diagnosis of a CFS according to the 2015 Institute of Medicine criteria\n* Fatigue Severity Scale (FSS) score ≥ 4\n* Ability to understand study procedures and provide informed consent\n\nExclusion Criteria\n\n* Comorbid psychiatric conditions (e.g., major depression, schizophrenia)\n* Current use of corticosteroids or immunomodulators\n* Known photosensitivity or dermatologic contraindications to LLLT\n* Participation in structured exercise programs more than twice weekly\n* Diagnosed malignancy or active infection -Not willing to be the part of study -","60 Years",{"count":299,"type":24},40,[27],"The goal of this clinical trial is to evaluate whether photobiomodulation therapy (low-level laser therapy) can reduce fatigue and improve quality of life in patients with chronic fatigue syndrome (CFS). The study will include adults aged 18-60 years diagnosed with chronic fatigue syndrome.\n\nThe main questions it aims to answer are:\n\nDoes photobiomodulation therapy significantly reduce fatigue levels as measured by the Fatigue Severity Scale (FSS) and Multidimensional Fatigue Inventory (MFI-20)? Does photobiomodulation therapy improve pain, functional capacity, sleep quality, and psychological well-being in patients with chronic fatigue syndrome?\n\nResearchers will compare the low-level laser therapy group with a placebo (sham laser) group to determine whether photobiomodulation therapy leads to greater improvements in fatigue, pain, and overall quality of life.\n\nParticipants will:\n\nReceive either active low-level laser therapy or placebo treatment three times per week for eight weeks Undergo assessments of fatigue, pain, functional capacity, quality of life, sleep quality, and psychological well-being at baseline and follow-up intervals (3, 6, and 12 months)",[303,30],"Chronic Fatigue Syndrome (CFS)",[305,306,307,308,309,310],"PHOTOBIOMODULATION","LOW-LEVEL LASER THERAPY","Chronic Fatigue Syndrome","Rehabilitation","Physiotherapy","Fatigue","2026-06-21",{"date":177,"type":37},{"date":314,"type":37},"2026-06-15",{"date":316,"type":24},"2026-09",{"name":318,"class":44},"University of Lahore",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":18,"sex":19,"minAge":89,"maxAge":297,"enrollmentInfo":326,"targetDuration":327,"studyType":116,"phases":4,"briefSummary":328,"conditions":329,"keywords":336,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100643860","multidimensional-determinants-of-functional-health-in-women-aged-45-60-100643860","NCT07667699","Multidimensional Determinants of Functional Health In Women Aged 45-60","Multidimensional Determinants and Structural Foundations of Functional Health In Women Aged 45-60: The Role of Muscle and Bone Health","Inclusion Criteria are:\n\n* Women aged 45 to 60 years\n* Ability to read and complete study questionnaires\n* Provision of written informed consent\n* Ability to complete physical performance assessments\n\nExclusion Criteria are:\n\n* Acute systemic illness\n* Active malignancy\n* Severe neurological or orthopedic impairment limiting physical performance assessment\n* Cognitive impairment precluding informed consent or questionnaire completion",{"count":23,"type":24},"1 Day","The goal of this observational study is to learn about the multidimensional determinants of functional health in women aged 45 to 60 years. The study will focus on the role of muscle strength, bone mineral density, body composition, physical activity, sleep quality, depressive symptoms, and menopause-related symptoms in functional health.\n\nThe main questions it aims to answer are:\n\n1. Does muscle strength contribute to functional health in women aged 45 to 60 years?\n2. Does bone mineral density contribute to functional health in women aged 45 to 60 years?\n3. How are physical activity, sleep quality, depressive symptoms, body composition, and menopause-related quality of life associated with functional health?\n\nParticipants will:\n\n* Undergo handgrip strength measurement\n* Perform a 30-second chair stand test\n* Undergo bone mineral density and body composition assessment\n* Complete questionnaires about physical activity, sleep quality, depressive symptoms, menopausal symptoms, and quality of life\n* Provide demographic and clinical information",[330,331,332,333,334,335,30],"Healthy","Perimenopausal Depression","Menopausal Complaints","Bone Mineral Density","Sarcopenia","Sleep Quality",[337,338,339,334,335,259],"Menopause","Perimenopause","Bone mineral density","2026-06-19",{"date":128,"type":37},{"date":314,"type":24},{"date":344,"type":24},"2026-12-31",{"name":346,"class":44},"Kartal City Hospital",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":18,"sex":53,"minAge":4,"maxAge":353,"enrollmentInfo":354,"targetDuration":327,"studyType":116,"phases":4,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":80},"100641492","functional-vision-and-quality-of-life-in-a-modern-society---with-emphasis-on-myopia-and-cerebral-visual-impairment-among-youth-100641492","NCT07653074","Functional Vision and Quality of Life in a Modern Society - With Emphasis on Myopia and Cerebral Visual Impairment Among Youth","Inclusion Criteria:\n\n* Healthy children\n\nExclusion Criteria:\n\n* Children with ophthalmological diagnosis followed frequently by the ophthalmological clinic","17 Years",{"count":355,"type":24},300,"Society has become increasingly digital, and many everyday services have been replaced by digital self-service solutions. This puts greater demands on our vision and our ability to interpret what we see. At the same time, the number of children with nearsightedness (myopia) has increased rapidly. In some parts of Asia, as many as 60-70% of students in seventh grade are nearsighted (1), and a similar trend may develop in Europe.\n\nNearsightedness is becoming a growing challenge in pediatric eye care. High myopia can lead to complications that require early detection and prevention. There are now several ways to slow down its progression, such as special contact lenses, glasses, and eye drops (2). However, the scientific evidence for these treatments varies, and there are currently no national or Nordic guidelines on how to use them. In addition, myopia may have a major impact on children's quality of life.\n\nCurrently, there is no validated Swedish questionnaire that measures vision related quality of life across all age groups in children and adolescents. To address this, researchers in the United States developed the Pediatric Eye Questionnaire (PedEyeQ) in 2019 (3). It is already available in English and Spanish and takes into account both the child's and the parent's perspectives on vision and daily life.\n\nThe aim of this study is to translate, culturally adapt and test the PedEyeQ in Swedish children and adolescents, and to investigate how common refractive errors, especially nearsightedness - are today compared to 20-30 years ago.\n\nThe study will include 300 healthy children and adolescents aged 0-17 years, divided into three age groups: 0-4 years, 5-11 years, and 12-17 years. Participants will be recruited through child health centers, preschools, and schools in the Örebro region.\n\nAll participants will visit the eye clinic for a detailed eye examination, including:\n\n* Testing distance and near visual acuity\n* Measuring eye refraction (with and without eye drops that temporarily relax the eye's focusing muscles)\n* Imaging the retina using Optical Coherence Tomography (OCT)\n* Measuring eye length and corneal shape\n* Checking eye pressure and contrast sensitivity\n\nChildren and parents will also answer questions about how the child's vision affects everyday life and wellbeing. For the youngest children (0-4 years), only parents will answer the questions.\n\nThe PedEyeQ will be translated into Swedish following the International Society for Pharmacoeconomics and Outcome Research (ISPOR) (4) guidelines to make sure it is culturally relevant and easy to understand. The Swedish version will then be tested to ensure it is accurate and reliable.\n\nAll information collected in the study will be stored securely and anonymously. The results will also be compared with data from a similar cohort conducted in the 1990s to see if vision problems have become more common over time (5).\n\nThis project will provide new knowledge about children's vision and quality of life in Sweden. A validated Swedish version of the PedEyeQ can be used both in healthcare and research to better understand how vision affects children's daily lives. The study will also offer updated information on the frequency of refractive errors among Swedish children and adolescents - knowledge that is essential for developing preventive strategies and improving eye care for the future.",[358,30],"Myopia",[259,360,361],"myopia","Sweden","2026-06-11",{"date":364,"type":37},"2026-06-17",{"date":366,"type":37},"2024-10-27",{"date":368,"type":24},"2029-05-30",{"name":370,"class":44},"Region Örebro County",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":25,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":80},"100642636","evaluation-of-the-impact-of-periodontitis-and-its-treatment-on-swallowing-functions-and-oral-quality-of-life-100642636","NCT07651579","Evaluation of the Impact of Periodontitis and Its Treatment on Swallowing Functions and Oral Quality of Life","FI-PAROCROC","Inclusion Criteria:\n\n* Patients treated at the university hospital and diagnosed with periodontitis\n* Adult patients who have provided informed consent\n* Patients enrolled in a social security system\n* Patients who speak and understand French.\n\nExclusion Criteria:\n\n* Minors\n* Pregnant or breastfeeding patients\n* Patients under legal protection or conservatorship\n* Patients who refuse to participate in the study",{"count":379,"type":24},44,[27],"The objective of this single-center prospective study is to evaluate the impact of periodontal treatment on masticatory performance in patients with periodontitis.\n\nParticipants will be asked to complete several questionnaires related to their oral health and quality of life. Functional masticatory tests and salivary flow measurements will also be performed.",[383,384,30],"Periodontitis","Periodontal Diseases",{"date":386,"type":37},"2026-06-16",{"date":388,"type":24},"2026-06-01",{"date":390,"type":24},"2028-06-01",{"name":392,"class":44},"University Hospital, Clermont-Ferrand",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":25,"phases":403,"briefSummary":404,"conditions":405,"keywords":409,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100642173","empowering-monterey-bay-residents-for-activated-collaborative-and-equitable-care-100642173","NCT07652359","Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care","EMBRACE - Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care","EMBRACE","Inclusion Criteria:\n\n* Participants must be receiving clinical care by a primary care physician in the Monterey area\n* Participants must be 18 years or older.\n* Participants must speak either English or Spanish.\n* Participants must be able to consent verbally in English or Spanish to all study procedures.\n* Participants must self-identify as a racial\u002Fethnic minorities OR identify as having low-income status\n\nExclusion Criteria:\n\n\\- Patients unable to respond to survey questions in either English or Spanish.",{"count":402,"type":24},138,[27],"The purpose of the EMBRACE Study is to evaluate whether a facilitated intervention improves shared decision-making (SDM) and patient activation among low-income and minority individuals more than usual care only. The ultimate goal is to enhance SDM and patient activation in care.",[406,30,407,408],"Shared Decision-Making","Advanced Illness","Terminal Illness",[410,411],"Goals of care","Advanced care planning","2026-06-10",{"date":364,"type":37},{"date":415,"type":24},"2026-10-01",{"date":417,"type":24},"2030-01-01",{"name":419,"class":44},"Stanford University",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":25,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":80},"100642536","dietary-quality-and-nutritional-adequacy-among-vegetarians-attending-the-european-institute-of-oncology-100642536","NCT07638839","Dietary Quality and Nutritional Adequacy Among Vegetarians Attending the European Institute of Oncology","Survey on Dietary Quality and Nutritional Adequacy Among Vegetarians Attending the European Institute of Oncology","VEGETARIANS","Inclusion Criteria:\n\n* pre or post-menopausal women, aged between 18 and 64;\n* healthy participants or high-risk cancer patients or patients with previous diagnosis of neoplasia\n* self-identifying as vegan (defined as excluding all animal products), or vegetarian (defined as excluding all animal products besides eggs and\u002For dairy) or semi-vegetarian (defined as excluding no animal products but limiting meat to \\\u003C 1× per week);\n* ability to understand and the willingness to sign a written informed consent document;\n\nExclusion Criteria:\n\n* any condition which, in the opinion of the investigator, may impede testing of the study hypothesis or make it unsafe to engage in the study (e.g., ulcerative colitis, Crohn's disease etc.);\n* any diagnosis of invasive neoplasia, within the previous 1 years, except non-melanoma skin cancer;\n* currently receiving chemotherapy, radiation, or immunotherapy as cancer treatment;\n* patients dependent on enteral or parental nutrition;\n* pregnancy or lactation;","64 Years",{"count":430,"type":24},150,[27],"Despite their health benefits, vegetarian dietary patterns can lead to malnutrition and micronutrient deficiencies if improperly managed, especially in oncological settings. This survey assesses dietary quality and adequacy in 150 women (18-64 years), further examining how a threemonth nutritional counseling intervention influences body composition, physical activity, and quality of life.",[434,30],"Nutritional Deficiencies",[436,437,438],"vegan","vegetarian","semivegetarian diet","2026-06-09",{"date":412,"type":37},{"date":442,"type":37},"2026-03-26",{"date":444,"type":24},"2028-01-26",{"name":446,"class":44},"European Institute of Oncology",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":455,"minAge":20,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":458,"conditions":459,"keywords":462,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":80},"100543375","ultrahypofractionated-adaptive-radiation-therapy-of-prostate-cancer-100543375","NCT06355050","Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer","Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer - Ultra-HART","ultraHART","Inclusion Criteria:\n\n* no androgen deprivation therapy within the last 2 months prior to RT\n* good performance status (Eastern Cooperative Oncology Group, ECOG, 0\u002F1)\n* no secondary malignancy","MALE","120 Years",{"count":430,"type":24},"In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.",[460,461,30],"Prostate Cancer","Adaptive Radiotherapy",[461,30,463],"Ultra-hypofractionation",{"date":362,"type":37},{"date":466,"type":37},"2026-04-01",{"date":468,"type":24},"2032-09-30",{"name":470,"class":44},"Jena University Hospital",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":25,"phases":481,"briefSummary":482,"conditions":483,"keywords":487,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":80},"100643615","digital-support-for-multiple-myeloma-quality-of-life-100643615","NCT07642362","Digital Support for Multiple Myeloma Quality of Life","Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)","DigiMyQoL","Inclusion Criteria:\n\n* Adult patients with newly diagnosed or relapsed\u002Frefractory multiple myeloma\n* Patients that are able to use the digital platform\u002Fapplication\n\nExclusion Criteria:\n\n* Patients that are not able to use the digital platform\u002Fapplication",{"count":480,"type":24},108,[27],"The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.\n\nSpecifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.",[484,485,486,30],"Multiple Myeloma","Patient Reported Outcome (PRO)","Supportive Care in Cancer",[488,489,490,491,492,493,494],"multiple myeloma","quality of life","qol","patient reported outcome","pro","digital oncology","supportive care","2026-06-07",{"date":362,"type":37},{"date":498,"type":37},"2025-02-27",{"date":500,"type":24},"2028-03",{"name":502,"class":503},"CareAcross","INDUSTRY",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":18,"sex":19,"minAge":511,"maxAge":214,"enrollmentInfo":512,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":514,"conditions":515,"keywords":518,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":531,"leadSponsor":533,"locationsCount":80},"100642790","temple-massager-system-study-in-women-ages-35-65-100642790","NCT07639658","Temple Massager System Study in Women Ages 35-65","Temple Massager System: Impact on Anxiety, Emotional Wellbeing, and Quality of Life in Women Aged 35-65","Inclusion Criteria:\n\n* Female, aged 35-65 years old, inclusive\n* Self-reported experience of daily stress, anxiety, tension headaches, facial tension, or TMJ-related discomfort\n* Headache frequency of 2 or more per week (self-reported)\n* If taking any prescription medication including SSRIs, anxiolytics, sleep medications, hormonal therapies, or blood pressure medications, must be on a stable dose for at least 4 weeks prior to study enrollment and throughout the course of the study\n* In good general health at the time of screening (Investigator discretion)\n* Able to read and understand English\n* Able to read, understand, and provide informed consent\n* Able to use a personal smartphone or tablet and access the study platform for daily data entry\n* Able to receive shipment of the study product at an address within the United States\n* Willing and able to use the Temple Massager System daily for 4 weeks\n\nExclusion Criteria:\n\n* No personal smartphone or tablet, no internet access, or unwilling to use the study platform\n* Known allergy or sensitivity to lavender oil, mango butter, shea butter, arnica, or St. John's Wort (Note: lavender sensitivity alone is not exclusionary; an aromatherapy sensitivity protocol applies)\n* Active skin infection or open wounds on the face or temple area\n* Diagnosed trigeminal neuralgia or other cranial nerve pathology\n* Diagnosed vascular issues affecting the head or face: temporal arteritis, aneurysm, or cerebrovascular malformations\n* Bleeding disorders: history of easy bruising or bleeding in the face\u002Fhead area, or current use of prescribed blood thinners (anticoagulants) such as Warfarin or Eliquis\n* Any surgery on the jaw, temples, or face within the last 6 months\n* Active inflammation: current redness, swelling, or extreme tenderness specifically over the temple arteries\n* Current use of prescription headache medications (triptans, topiramate, muscle relaxants, beta-blockers for migraine prophylaxis, or other prescription medications taken primarily for headache management)\n* Participants currently taking any prescribed medication for sleep or anxiety must be on a stable dose (no dose changes within the past 30 days) to be eligible; participants not on a stable dose are excluded\n* Current participation in another interventional study\n* Diagnosed Generalized Anxiety Disorder (GAD)\n* Currently pregnant, planning to become pregnant during the study period, or breastfeeding\n* Planned surgical procedure during the study period\n* Significant illness, disease, or condition which, in the opinion of the Principal Investigator, may impact the ability to participate in the study or impact the study outcomes\n* Unlikely for any reason to be able to comply with the study or considered unsuited for participation by the Principal Investigator","35 Years",{"count":513,"type":24},48,"The goal of this observational study is to learn how the Temple Massager System affects stress, emotional wellbeing, sleep, and quality of life in women aged 35 to 65.\n\nThe Temple Massager System is a non-electric, drug-free hand-held device used for self-massage of the temple area. The system also includes a body lotion and an optional lavender aromatherapy. It is sold as a general wellness product.\n\nThe main questions this study aims to answer are:\n\nDoes daily use of the Temple Massager System lower self-reported stress and improve emotional wellbeing over 4 weeks? Does daily use improve self-reported sleep quality and overall quality of life?\n\nThis is a single-arm observational study. There is no placebo or comparison group. Researchers will compare how participants feel before they start using the device to how they feel after 4 weeks of daily use.\n\nParticipants will:\n\nReceive a Temple Massager System at no cost Complete a 1-week baseline period before using the device Use the device once a day for at least 5 minutes for 4 weeks Answer short daily questions about device use, headaches, and over-the-counter medication use Complete weekly check-in surveys about stress, mood, and sleep Complete longer surveys at the start and end of the study Keep the device after the study ends\n\nThe study runs for 5 weeks per participant and takes place entirely from home through a secure app-based platform. No clinic visits are required.",[516,517,335,30],"Tension Headaches","Stress",[519,520,521,522,523,524,525,526,527],"Stress relief","Wellness","Massage device","Temple massage","Facial tension","Relaxation","Women's Health","Decentralized trial","Observational study","2026-06-05",{"date":412,"type":37},{"date":412,"type":24},{"date":532,"type":24},"2026-09-30",{"name":534,"class":503},"MOQ Collective, Ltd",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":53,"minAge":20,"maxAge":4,"enrollmentInfo":542,"targetDuration":543,"studyType":116,"phases":4,"briefSummary":544,"conditions":545,"keywords":550,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":561,"leadSponsor":563,"locationsCount":4},"100643721","evolution-of-physical-frailty-and-patient-reported-outcome-measures-in-kidney-transplant-candidates-a-mixed-methods-longitudinal-study-protocol-100643721","NCT07607041","Evolution of Physical Frailty and Patient-Reported Outcome Measures in Kidney Transplant Candidates: A Mixed-Methods Longitudinal Study Protocol","Longitudinal Tracking of Physical Frailty and Health-Related Quality of Life Through Patient-Reported Outcome Measures in Adult Candidates on the Kidney Transplant Waiting List","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosed with Stage 5 chronic kidney disease (CKD).\n* Currently undergoing clinical evaluation for or actively listed on the deceased-donor kidney transplant waiting list at Hospital del Mar (Barcelona).\n* Cognitive and physical ability to understand and provide written informed consent.\n* Ability to use or have regular access to a digital device (smartphone or tablet) for electronic Patient-Reported Outcome Measures (ePROMs) completion.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or active psychiatric disorders that prevent the reliable completion of questionnaires or physical tests.\n* Major physical disability that precludes the objective assessment of gait speed or handgrip strength (e.g., bilateral lower limb amputation or severe dominant hand deformity).\n* Acute medical illness requiring hospitalization at the time of enrolment.\n* Total language barrier that prevents understanding the study components or the qualitative interview.",{"count":430,"type":24},"24 Months","This study looks at how the physical and emotional health of people changes while they wait for a kidney transplant. Waiting for an organ can take a long time. During this period, some patients become \"frail.\" This means they lose strength and are at a higher risk for health problems.\n\nThe main goal is to follow these patients over time to better understand their needs. Researchers will use a mobile application to collect Patient-Reported Outcome Measures (PROMs) directly from patients about how they feel and their quality of life. The study will also include personal interviews to learn about the patients' experiences and any difficulties they face when using technology.\n\nThe results of this study will help to: • Identify early which patients are losing strength or health. • Improve the support that nurses provide during the transplant waiting period. • Make sure that digital health tools are easy for everyone to use.\n\nIn short, this work aims to help patients reach the day of their surgery in the best possible condition.",[546,547,30,548,549],"Kidney Failure, Chronic","Frailty","Kidney Transplantation","Patient Reported Outcome Measures",[548,551,552,227,553,554,555,556,557],"Waiting Lists","Health-Related Quality of Life","Longitudinal Studies","Mixed Methods Research","Hermeneutics","Patient-Centered Care","Technology Assessment, Biomedical",{"date":559,"type":37},"2026-06-08",{"date":202,"type":24},{"date":562,"type":24},"2028-07",{"name":564,"class":44},"Hospital del Mar",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":18,"sex":53,"minAge":214,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":25,"phases":573,"briefSummary":574,"conditions":575,"keywords":581,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":592,"locationsCount":80},"100643588","strength-for-caregiving-100643588","NCT07615205","Strength for Caregiving","Strength for Caregiving - A Nutrition Coaching Model to Support Caregivers' Wellbeing and Functional Ability","Inclusion Criteria:\n\n* Born in 1961 or earlier (i.e. aged over 65 years)\n* Adequate Finnish language skills\n* Able to give informed written consent\n* Acting as a caregiver (with or without a formal caregiver contract) in the areas of Pori, Rauma, or Kankaanpää\n* Normal cognition (participants with an MMSE score below 24 will be assessed by the responsible physician)\n\nExclusion Criteria:\n\n* Serious acute illness or inability to act as an informal caregiver\n* A condition, ailment, or underlying health risk that is poorly controlled and that participation in the study could exacerbate, or a terminal illness (Consultation of the doctor in charge, if necessary, in unclear cases)\n* Born in 1961 or later (i.e. aged under 65 years)\n* Substance abuse based on the AUDIT-C score (consultation of the doctor in charge)",{"count":173,"type":24},[27],"The goal of this single-arm pre-post study is to promote elderly (≥ 65 years) family caregivers' dietary habits, well-being and functional capacity through comprehensive nutritional guidance. The main goals of the project are to:\n\n* Improve the well-being, resilience, and functional capacity of the participating family caregivers through the comprehensive nutritional counseling implemented as part of the project.\n* Create a nutrition counseling model that promotes the well-being and coping of family caregivers and can also be utilized in well-being services counties after the project concludes.\n* Produce up-to-date and practical nutrition materials for family caregivers.\n\nThe project participants will participate in two individual nutrition counselling sessions and three group nutrition counseling sessions over a period of ten months.\n\nResearchers will compare the results of the participants' baseline and final measurements to see if nutrition counseling is effective in improving family caregivers' well-being, resilience, and functional capacity.",[576,577,578,30,579,580],"Mental Well-being","Muscle Strengh","Dietary Habits","Nutritional Status","Functional Capacity",[582,583,584,585,259,586,69],"Nutrition","Caregiver","mental well-being","Functional capacity","Nutritional counseling","2026-06-04",{"date":559,"type":37},{"date":316,"type":24},{"date":591,"type":24},"2027-11",{"name":593,"class":44},"Susanna Kunvik",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":18,"sex":53,"minAge":602,"maxAge":20,"enrollmentInfo":603,"targetDuration":605,"studyType":116,"phases":4,"briefSummary":606,"conditions":607,"keywords":612,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":617,"startDateStruct":618,"completionDateStruct":619,"leadSponsor":621,"locationsCount":80},"100639547","quality-of-life-and-pain-after-appendectomy-in-children-100639547","NCT07629362","Quality of Life and Pain After Appendectomy in Children","Chronic Postoperative Pain After Appendectomy: A Prospective Observational Study","CAPA-Peds","Inclusion Criteria:\n\nChildren between the ages of 8-18 years who underwent appendectomy, who had ASA physical status I-II\n\nExclusion Criteria:\n\nChildren who aged under 8 and over 18 years, who had American Society of Anesthesiologists (ASA) physical status III or higher, who had a history of previous surgery in the right lower abdominal quadrant, who had psychiatric disorders, who had preoperative chronic abdominal pain","8 Years",{"count":604,"type":24},231,"3 Months","Acute appendicitis is one of the most common emergency general surgical conditions worldwide and represents the leading cause of emergency abdominal surgery in children. In some cases, appendectomy may result in persistent or recurrent pain in the right iliac fossa, which may negatively affect quality of life, particularly in children. The primary aim of this study is to determine the prevalence of chronic pain at the third postoperative month in pediatric patients who underwent appendectomy. The age, sex, body mass index, and comorbidities of patients aged 8-18 years who underwent appendectomy will be recorded. Pain in children who met the inclusion criteria was assessed using the Numeric Rating Scale (NRS). To evaluate the effects of pain on quality of life, the child and parent versions of the Pediatric Quality of Life Inventory (PedsQL) were administered at the third postoperative month. In addition, the Functional Disability Inventory (FDI) was used at the third postoperative month to assess the impact of pain on the patient's functional status.",[608,30,609,610,611],"Chronic Pain, Postoperative","Functional Ability","Appendectomy","Numerical Rating Scale",[613,614,615,616],"chronic pain","appendectomy","FDI","PedsQL",{"date":528,"type":37},{"date":77,"type":24},{"date":620,"type":24},"2027-02-25",{"name":622,"class":623},"Kocaeli City Hospital","OTHER_GOV",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":53,"minAge":297,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":25,"phases":632,"briefSummary":633,"conditions":634,"keywords":642,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":658,"locationsCount":80},"100376320","impact-of-positive-airway-pressure-therapy-on-clinical-outcomes-in-older-veterans-with-chronic-obstructive-pulmonary-disease-and-comorbid-obstructive-sleep-apnea-overlap-syndrome-100376320","NCT04179981","Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)","Inclusion Criteria:\n\n* OSA with moderate-to-severe disease, AHI 20 per hour by in-lab polysomnography with concomitant moderate-severe COPD based on pulmonary function tests (PFTS) and with past significant history (\\>10 pack-years) of smoking\n* Male or female gender\n* Age greater than or equal to 60 years\n* Stable treatment regimen for COPD\n\nExclusion Criteria:\n\n* Current or prior treatment with PAP or oral appliance\n* Central sleep apnea defined as central apnea index \\>5 per hour and comprising 50% of AHI\n* Known primary neuromuscular diseases\n* Disorders that may impact cognitive function including:\n\n  * neurodegenerative disorders\n  * traumatic brain injury\n* untreated PTSD and\u002For history of learning disability\n* Medicines that may cause or alter sleepiness: sedative hypnotics, or stimulants as these may alter the results\n* Patient is actively suicidal due to depression, unstable mental health condition\n* Epworth sleepiness score \\>16 (severe sleepiness) or a near-miss or prior automobile accident due to sleepiness within the past 12 months\n* Narcolepsy is the primary sleep disorder, with requirement of stimulant medications\n* Employed as a commercial driver or operating heavy machinery\n* On long-term oxygen therapy prior to start of study, more than 12 hr\u002Fday\n* Patients is unable to use either a nasal or face mask (e.g., facial trauma, claustrophobia)\n* Consumption of \\>3 alcoholic beverages per day or current use of some illicit drugs, as these may contribute to cognitive deficits\n* Patients who cannot give informed consent\n* Patients receiving hospice care\n* Pregnant women due to unknown risks",{"count":631,"type":24},668,[27],"Obstructive sleep apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD) are highly prevalent chronic respiratory diseases in the Veteran population. OSA co-occurring with COPD, known as Overlap Syndrome (OVS), is a complex chronic medical condition associated with grave consequences. OVS is highly prevalent in Veterans. Veterans with OVS may be at increased risk for cognitive deficits, poor sleep quality as well as a reduced quality of life (QoL). The overall objective is to study the effects of positive airway pressure therapy on clinical outcomes in patients with OVS.",[635,119,636,637,30,638,639,640,641],"Sleep Apnea Syndrome","COPD","Overlap Syndrome","Neurocognitive Function","Sleepiness","Elderly","Positive Airway Pressure",[643,644,645,646,647,648,649,650,651,489,652],"Apnea","Sleep Apnea Syndromes","Sleep Apnea, Obstructive","Nervous System Diseases","Respiration Disorders","Respiratory Tract Diseases","Signs and Symptoms, Respiratory","positive airway pressure","cognitive function","sleepiness","2026-06-03",{"date":528,"type":37},{"date":656,"type":37},"2020-12-01",{"date":103,"type":24},{"name":659,"class":660},"VA Office of Research and Development","FED",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":4,"eligibilityCriteria":667,"healthyVolunteers":18,"sex":53,"minAge":668,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":25,"phases":671,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":678,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":80},"100602422","capable-care--connect-100602422","NCT07123298","CAPABLE Care + Connect","CAPABLE Care + Connect: Pilot Feasibility of Implementing CAPABLE Into Homebased Primary Care","Inclusion Criteria:\n\n* Any patient currently in JHOME\n* At risk for or experiencing social isolation as defined by the Lubben Social Network Scale 6 item score less than or equal 12 points or loneliness as defined by the UCLA Loneliness Scale 3 item score of 6 to 9 points\n* Cognitive inclusion criteria Montreal Cognitive Assessment (MOCA) \\>23 as determined by referring JHOME study team member provider\n* English speaking (measures are standardized in English)\n* Ability to participate in an approximately 45-60 min virtual or in person meeting\n* Eligible for CAPABLE\n* 50 years or older\n* Not hospitalized over night more than 4 times in the last 12 months\n* Have some difficulty with any ADL\n* Cognitively intact\n* Live in Baltimore County or Baltimore City\n* Not receiving active cancer treatment\n* Interested in participating in CAPABLE Care partners will be included if the care partners provide \\> 10 hours of care\u002Fweek\n\nExclusion Criteria:\n\n* Terminally ill\n* live in long term care setting\n* receiving active cancer treatment\n\nStandard of Care\u002FComparison group Inclusion Criteria:\n\n• Any patient currently in JHOME who did not receive the CAPABLE intervention","50 Years",{"count":670,"type":24},450,[27],"In this evaluation scale-up research project, the investigators seek to test an implementation of CAPABLE on the infrastructure of home-based primary care for individuals who may experience social isolation and\u002For loneliness. These two home-based care programs may improve each other and provide opportunity to further improve quality of life for people living with disabilities and the caregivers. The purpose of this mixed methods study is to adapt and test CAPABLE, an existing evidence-based program, to a new target population with the scalable infrastructure of home-based primary care.",[674,675,676,30,62,677],"Social Isolation in Older Adults","Social Isolation or Loneliness","Social Isolation","Homebound Persons",{"date":39,"type":37},{"date":680,"type":37},"2025-08-14",{"date":682,"type":24},"2027-05",{"name":79,"class":44},{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":689,"acronym":690,"eligibilityCriteria":691,"healthyVolunteers":12,"sex":19,"minAge":692,"maxAge":693,"enrollmentInfo":694,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":696,"conditions":697,"keywords":706,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":711,"lastUpdatePostDateStruct":712,"startDateStruct":713,"completionDateStruct":714,"leadSponsor":716,"locationsCount":4},"100637786","prospectivefemaleaya---late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100637786","NCT07622420","ProspectiveFemaleAYA - Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes (ProspectiveFemaleAYA)","FemFertilAYA","Inclusion Criteria:\n\n* Female cancer patients aged between 15 and 39 years at diagnosis.\n* Receiving a diagnosis of primary cancer 01\u002F01\u002F2025 or later\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For gynaecological surgery.\n* Detailed information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis.\n* Treated by surgery alone (except gynaecological surgery).\n* Patients with relapse or secondary malignant neoplasms at time of inclusion or having received already treatments for cancer\n* Adult individuals subject of a measure of legal protection and\u002For patients with severe mental disorders.","15 Years","39 Years",{"count":695,"type":24},3000,"In the past two decades, the evidence-based knowledge on the prevalence and risk factors for gonads impairment, including infertility, following cancer and numerous cancer treatment regimen has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility and pregnancy potential, including the use and success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex as more recent treatment regimen have continuously also implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questionsis highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale registry of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian dysfunction and\u002For fertility impairment and premature ovarian insufficiency following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Fhormonal treatment and patients' satisfaction related to these procedures in Europe will be analysed to support patient-centric care.\n\nReproductive health counselling should not be limited to evaluating the risk of gonadotoxicity and offering fertility preservation to those at risk. It should also include evaluating the impact on post-treatment sexuality, menopausal symptoms management, and the counselling on contraception.\n\nIn addition to clinical information, whole genome sequence data will be generated for selected study participants with evidence of varying impact of gonadotoxic therapies on reproductive function to find genetic variants associated with risk of reproductive and organ toxicity.\n\nThe data collection will focus on all different cancer diseases, including diseases which are less common such as different types of sarcomas. This will be a significant development to the current state of information in existing registries.\n\nThe primary objectives of this prospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n1. To establish a database with relevant clinical characteristics at time of diagnosis, cancer therapy received and post-cancer clinical and reproductive outcomes by following AYA cancer patients longitudinally.\n2. To evaluate the effect of cancer therapies on ovarian function and reproductive potential.\n3. To evaluate fertility preservation measures performed, their risks and efficacy.\n4. To evaluate the impact of fertility preservation measures on the risk of cancer relapse.\n5. To evaluate occurrence of pregnancies\u002Flive births naturally conceived (including unplanned) or through medical assistance post-cancer and the obstetrical complications and neonatal health following the use of cryopreserved oocytes or gonadal tissue.\n6. To set up a genetic database based on whole genome sequencing of AYAs of the cohort. For this objective a Substudy 1 : \" Development of risk prediction models based on clinical and genetic data \" will be conducted.\n7. To develop prediction models for organ toxicities in cancer patients (objective included in Substudy 1).\n8. To evaluate the effect of cancer therapies on sexuality and quality of life. For this objective a Substudy 2 : \"Sexual Health\" will be conducted.\n9. To evaluate the use and counselling on contraception. For this objective, a Substudy 3 : \"Contraception\" will be conducted.\n10. To describe management of treatment-induced premature ovarian insufficiency (POI) and menopausal symptoms. For this objective a Substudy 4 \"Management of POI and Menopause Symptoms\" will be conducted.\n11. To explore patient's satisfaction receiving counseling and\u002For undergoing fertility preservation. For this objective a Substudy 5 on \"Satisfaction with Fertility Preservation\" will be conducted.",[698,699,700,701,702,30,703,704,705],"Cancer","Cancer in Pregnancy","Infertility","In Vitro Fertilisation (IVF) Treatment","Late Effects","Sexual Health Quality of Life","POI","Contraception Use",[707,708,709,710],"cancer therapy induced late effects","AYA cancer survivors","infertility as a late effect of cancer","late effects prediction","2026-05-27",{"date":653,"type":37},{"date":388,"type":24},{"date":715,"type":24},"2035-05-31",{"name":717,"class":44},"Karolinska Institutet"]